Marbury T C, Lee C S, Perchalski R J, Wilder B J
Am J Hosp Pharm. 1981 Nov;38(11):1757-60.
Clearance of ethosuximide by hemodialysis was studied. Four patients with chronic renal disease supported by hemodialysis were given ethosuximide 500 mg four hours before dialysis. Samples of arterial and venous blood and dialysate were collected before and during the four-hour dialysis procedure. Ethosuximide concentration was measured by gas-liquid chromatography. The extraction efficiency for the dialysis systems used in this study ranged from 61.1 to 100%, and dialysis clearance was from 122.3 to 156.3 ml/min. Recovery of ethosuximide from the dialysate was 38.8 to 52.4% of the administered dose. Hemodialysis reduced the elimination half-life of ethosuximide from a presumable value of 55 hours to an average of 3.5 hours. The authors concluded that ethosuximide is dialyzable. Hemodialysis patients concurrently receiving ethosuximide may require a supplemental dose or an altered ethosuximide dosing schedule. Because hemodialysis quickly clears ethosuximide, it may be useful in treating ethosuximide overdosage.
研究了血液透析对乙琥胺的清除作用。对4例接受血液透析维持治疗的慢性肾病患者,在透析前4小时给予500毫克乙琥胺。在4小时的透析过程之前和期间采集动脉血、静脉血和透析液样本。采用气液色谱法测定乙琥胺浓度。本研究中使用的透析系统的萃取效率为61.1%至100%,透析清除率为122.3至156.3毫升/分钟。从透析液中回收的乙琥胺占给药剂量的38.8%至52.4%。血液透析使乙琥胺的消除半衰期从推测的55小时缩短至平均3.5小时。作者得出结论,乙琥胺可被透析清除。同时接受乙琥胺治疗的血液透析患者可能需要补充剂量或调整乙琥胺给药方案。由于血液透析能迅速清除乙琥胺,因此它可能对治疗乙琥胺过量有用。